This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Cadrenal Therapeutics (NasdaqCM:CVKD) 2025 Conference September 30, 2025 03:30 PM ET Company ParticipantsTerry Ferguson - Chief Medical OfficerModeratorAll right, hello everyone. Thank you so much for joining us throughout the day here at the Lytham Partners Fall 2025 Investor Conference. Again, my name is Robert Blum, Managing Partner here at Lytham Partners. Coming up next, we have a presentation from Cadrenal Therapeutics, company trades under the ticker symbol CVKD on the NASDAQ. Presenting from the com ...

I have covered Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) twice before, and on both occasions, my predictions of share price performance on the basis of fundamental analysis were proved correct over the following months. MyI have been investing in the stock market since I was 17 years old, and over the 25+ years since I have learned the joy of compounding, the value of dividend reinvesting, and the principle that patient investing through good times and bad brings the greatest rewards. I believe the ke ...

The U.S. Food and Drug Administration has approved Novartis' oral treatment for patients with type of chronic inflammatory skin disease, the company said on Tuesday. ...

In this article, we will look at the Top 12 Blue Chip Stocks to Buy At 52-Week Lows.On September 30, Elyse Ausenbaugh, Head of Investment Strategy at JPMorgan Wealth Management, joined CNBC for an interview to discuss the current market rally. She noted that there is a strong momentum going forward in 2025, which is likely to continue in 2026 as well. She sees improvements in the macroeconomic environment and anticipates powerful tailwinds from significant investments in AI.She highlighted that the current ...

Pfizer has agreed to lower the cost of prescription drugs for Medicaid under a deal struck with the Trump administration, President Donald Trump said Tuesday as he promised similar deals with other drugmakers under the threat of tariffs.Trump made the announcement at the White House alongside Pfizer CEO Albert Bourla just hours ahead of a possible government shutdown in a partisan standoff over health care and spending.Pfizer Inc., one of the largest U.S. drugmakers, produces the COVID-19 vaccine Comirnaty ...

Ad hoc announcement pursuant to Art. 53 LR Rhapsido helps to inhibit release of histamine and proinflammatory mediators by targeting BTK, offering unique approach to CSU treatment1Well-controlled disease observed as fast as two weeks, with demonstrated safety profile that requires no lab monitoring1 1.7 million people in US live with CSU; more than half remain symptomatic despite increasing doses of antihistamines2,3Remibrutinib also in clinical development for chronic inducible urticaria, food allergy, and ...

Ad hoc announcement pursuant to Art. 53 LR Rhapsido helps to inhibit release of histamine and proinflammatory mediators by targeting BTK, offering unique approach to CSU treatment1Well-controlled disease observed as fast as two weeks, with demonstrated safety profile that requires no lab monitoring1   1.7 million people in US live with CSU; more than half remain symptomatic despite increasing doses of antihistamines2,3Remibrutinib also in clinical development for chronic inducible urticaria, food allergy, a ...

In this articlePFEMTSRThomas Fuller | SOPA Images | Lightrocket | Getty ImagesA version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.Pfizer's newest bet on obesity is already showing promise. The company last week said it would buy weight loss drugmaker Metsera in an up to $7.3 billion deal, including future payments, that is expected to close at the end of the year. Just a week ...

Pharmaceutical stocks are enjoying tailwinds today, after President Donald Trump announced the launch of a direct-to-consumer website dubbed "TrumpRX." The new platform will enable Americans to buy their prescription drugs straight from the federal government. The White House said "virtually all drugs" would be available, with an 80% price discount for many of them. The White House made the announcement alongside Pfizer Inc (NYSE:PFE) CEO  Albert Bourla. The company is expected to lower drug prices for Medi ...